 AstraZeneca PLC LSE:AZN has increased its earnings guidance after a strong quarter during which EPS grew by 70 at constant exchange rates. The Anglo-Swedish drugs giant says it now expects 2022 core EPS to increase by the high-twenties to low-thirties percent. 